As a leading research service provider, Protheragen has established a comprehensive, end-to-end therapy development platform to accelerate the translation of innovative therapeutics for a wide range of ophthalmic diseases. Our one-stop pre-clinical approach integrates cutting-edge technologies, deep scientific expertise, and seamless cross-functional collaboration to systematically advance promising drug and therapy candidates through the critical pre-clinical phase.
Diagnostics Development Services
Protheragen is committed to pushing the boundaries of diagnostic technology. Our pre-clinical diagnostics development services focus on creating tools that can detect ophthalmic diseases at their earliest stages.
Therapeutics Development Services
From small-molecule inhibitors and biologics to gene therapies and regenerative approaches, our researchers work tirelessly to translate the latest scientific breakthroughs into promising pre-clinical leads.
Disease Model Development Services
Our team has established a comprehensive suite of advanced in vitro and in vivo models, including organotypic cultures, patient-derived xenografts, and genetically engineered animal systems, to recapitulate the complexities of ophthalmic diseases.
Drug Safety Evaluation Services
Ensuring the safety and tolerability of ophthalmic drug candidates is a top priority for Protheragen. Our pre-clinical drug safety evaluation services encompass extensive toxicology studies and ocular irritation assessments.
Our pharmacokinetics experts leverage advanced modeling and simulation techniques, coupled with in-depth bioavailability studies, to guide the formulation and optimization of innovative drug delivery system.
Protheragen provides comprehensive clinical research services for ophthalmic drug development, covering IIT and IST trials from protocol design through data analysis, with expertise in ocular therapeutics.
| Service Category | Detailed Service Descriptions | Core Value for Ophthalmic R&D |
| Target Identification & Validation | Identify novel molecular and cellular targets associated with ophthalmic diseases (e.g., glaucoma, AMD, diabetic retinopathy); validate target relevance via in vitro and in vivo ophthalmic disease models; conduct target druggability assessment. | Establishes a scientific foundation for drug discovery, ensuring R&D efforts focus on clinically relevant and pharmacologically feasible targets for ocular disorders. |
| Hit Discovery & Lead Optimization | Perform high-throughput screening (HTS) and fragment-based screening for ocular drug hits; conduct lead compound optimization (potency, selectivity, ocular bioavailability, solubility); structure-activity relationship (SAR) analysis for ophthalmic candidates. | Accelerates the discovery of high-quality lead compounds tailored for ocular delivery and efficacy, reducing late-stage R&D failure risks for ophthalmic therapeutics. |
| Formulation Development | Design and develop ophthalmic-specific formulations (eye drops, intravitreal injections, ocular inserts, sustained-release formulations); optimize formulation stability, sterility, and ocular tolerability; conduct formulation compatibility studies. | Addresses the unique challenges of ocular drug delivery (e.g., corneal barrier, short residence time), enhancing drug bioavailability and patient compliance for ophthalmic treatments. |
| In Vitro Pharmacology Assays | Develop and run custom in vitro assays for ocular efficacy (e.g., retinal cell viability, angiogenesis inhibition, intraocular pressure modulation); conduct target engagement and mechanism-of-action (MoA) studies for ophthalmic drugs. | Provides rapid, cost-effective pre-clinical efficacy data, validating drug activity in ocular-relevant cellular and biochemical systems before in vivo studies. |
| In Vivo Efficacy Evaluation | Conduct efficacy studies in validated ophthalmic disease animal models (glaucoma, dry eye, macular degeneration, uveitis); perform quantitative ocular endpoint assessments (e.g., fundus imaging, OCT, IOP measurement); dose-response and PK/PD correlation analysis. | Demonstrates in vivo drug efficacy in physiologically relevant ocular disease models, supporting IND-enabling studies for ophthalmic therapeutics. |
| Bioanalysis & Biomarker Development | Develop and validate bioanalytical methods for quantifying ocular drugs/metabolites (aqueous humor, vitreous, retinal tissue); identify and validate ophthalmic disease-specific biomarkers (diagnostic, prognostic, efficacy); biomarker assay development and implementation. | Enables accurate quantification of drug exposure in ocular tissues and provides actionable biomarkers to track disease progression and drug response in ophthalmic R&D. |
| Ocular Drug Delivery System (DDS) Development | Engineer novel ocular DDS (nanoparticles, liposomes, hydrogels, iontophoresis-based delivery); evaluate DDS performance (ocular targeting, release kinetics, biocompatibility); optimize DDS for improved intraocular drug distribution. | Overcomes ocular delivery barriers, enabling targeted and sustained drug delivery to specific ocular tissues (retina, choroid, trabecular meshwork) and improving therapeutic index for ophthalmic drugs. |
| Immunogenicity Assessment | Conduct pre-clinical immunogenicity studies for biologic ophthalmic drugs (antibodies, gene therapies, cell therapies); detect anti-drug antibodies (ADAs) in ocular and systemic samples; assess immunogenicity impact on drug efficacy and safety. | Mitigates immunogenicity risks for biologic ophthalmic therapeutics, a critical challenge for intraocular biologic delivery, and ensures long-term drug safety and efficacy. |
| Stability Studies | Perform accelerated and real-time stability testing for ophthalmic drug formulations; conduct stress testing (temperature, light, oxidation) for ocular drugs; evaluate packaging compatibility for ophthalmic products. | Ensures the chemical, physical, and microbial stability of ophthalmic formulations throughout the pre-clinical and clinical stages, supporting product shelf-life determination and packaging optimization. |
By seamlessly integrating these pre-clinical capabilities, Protheragen offers a truly one-stop solution for advancing ophthalmic disease therapies from concept to the clinical trial stage. Our cross-functional teams work in close collaboration to identify and address challenges at every step of the development pipeline, ensuring the rapid and efficient progression of promising candidates. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
As a research service provider, Protehragen offers a comprehensive range of cutting-edge services to advance the development of innovative therapies and unlock the future of rare eye disease therapeutics.
Congenital Ophthalmic Diseases
Hereditary Ophthalmic Diseases
Infectious Ophthalmic Diseases
Copyright © Protheragen. All rights reserved.
